Morgan Stanley is a buy on weakness with strong dividend growth and projected revenue growth in Q4 2024 and early 2025. Click for our MS earnings preview.

Vir Biotechnology (VIR) stock was upgraded by Morgan Stanley after the company posted trial data for two antitumor agents ...

JP Morgan analyst Kian Abouhossein maintained a Neutral rating and boosted the price target from $100 to $104 on Dec. 6, 2024 ...

Oklahoma-based financial advisors John “David” Veitch and his son Drew are joining Raymond James’ employee advisor channel, ...

The broad-based S&P 500 (SNPINDEX: ^GSPC) returned 23%, the blue-chip Dow Jones Industrial Average (DJINDICES: ^DJI) advanced ...

Fintel reports that on January 8, 2025, Morgan Stanley upgraded their outlook for NetEase (OTCPK:NETTF) from Equal-Weight to ...

Morgan Stanley highlighted that the RBI has lifted restrictions on Asirvad Micro Finance with immediate effect. Morgan ...

Nomura also expects Tata Motors to transition from a net debt position of Rs 22,000 crore in Q2 to achieving net cash of Rs 86 per share by FY27. The stock is currently trading at 4.2x FY27 EV/EBITDA, ...

Morgan Stanleys Chief US Equity Strategist, Mike Wilson, forecasts a volatile first half of 2025, with recovery prospects ...

Morgan Stanley (MS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook ...

Discover the RIL Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a top-performing ...

Reliance Industries' stock valuation hits a 3-year low, offering a strong risk-reward opportunity. Analysts foresee growth in ...